GT Biopharma, Inc. (GTBP) shareholders
Close on Nov 17, 2026Market cap $143.45MP/E –Yield –
Ownership
Who owns GT Biopharma's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Five Narrow Lane LP | 253,388 | 9.99% | 13G (passive) | May 13, 2025 |
| Cytovance Biologics Inc | 219,457 | 9.80% | 13G (passive) amendment | Sep 30, 2024 |
| RainForest Partners, LLC | 180,258 | 9.99% | 13G (passive) | Sep 15, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Martin Breen | CEO and Director | 856,218 | 1.90% | Sep 8, 2025 |
| Alan Louis Urban | Chief Financial Officer | – | – | Sep 8, 2025 |
| Charles J. Casamento | Director | – | – | Sep 8, 2025 |
| Hilary Kramer | Director | – | – | Sep 8, 2025 |
| David C. Mun-Gavin | Director | – | – | Sep 8, 2025 |
| Andrew J. Ritter | Director | – | – | May 29, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Manu Ohri CFO & Secretary | Aug 11, 2023 | Award | +200,000 | $0.29 | $58.00K | 200,000 |
| Manu Ohri CFO & Secretary | Aug 11, 2023 | Other | −200,000 | $0.29 | $58.00K | 0 |
| Manu Ohri CFO & Secretary | Aug 11, 2023 | Other | +200,000 | $0.29 | $58.00K | 300,000 |
| Michael Martin Breen Executive Chairman/Interim CEO, Director | Aug 11, 2023 | Award | +200,000 | $0.29 | $58.00K | 856,218 |
| Michael Martin Breen Executive Chairman/Interim CEO, Director | Apr 11, 2023 | Buy | +50,000 | $0.50 | $25.00K | 656,218 |
| Manu Ohri CFO & Secretary | Apr 6, 2023 | Buy | +50,000 | $0.50 | $25.00K | 50,000 |
| Manu Ohri CFO & Secretary | Jul 15, 2022 | Other | +100,000 | – | – | 100,000 |
| Manu Ohri CFO & Secretary | Jul 15, 2022 | Other | −100,000 | – | – | 0 |
| Manu Ohri CFO & Secretary | Jul 15, 2022 | Award | +100,000 | – | – | 100,000 |
| Michael Martin Breen Exec. Chair. and Interim CEO, Director | Jul 15, 2022 | Award | +278,058 | – | – | 606,218 |
| Michael Martin Breen Director | Feb 25, 2021 | Conversion | +40,243 | $3.40 | $136.83K | 318,301 |
| Michael Martin Breen Director | Feb 25, 2021 | Conversion | +9,859 | $3.40 | $33.52K | 328,160 |
| Gregory Berk Director | Feb 16, 2021 | Award | +278,058 | – | – | 278,058 |
| Michael Martin Breen Director | Feb 16, 2021 | Award | +278,058 | – | – | 278,058 |
| Bruce Wendel Director | Feb 16, 2021 | Award | +347,572 | – | – | 352,655 |
| Bruce Wendel Director | Dec 22, 2020 | Buy | +1,374 | $8.87 | $12.19K | 4,642 |
| Bruce Wendel Director | Dec 22, 2020 | Buy | +441 | $8.73 | $3.85K | 5,083 |
| Steven W. Weldon – | Dec 22, 2020 | Sale(10b5-1 plan) | −47,978 | $0.40 | $19.19K | 3,720,000 |
| Steven W. Weldon – | Dec 21, 2020 | Sale(10b5-1 plan) | −35,722 | $0.34 | $12.15K | 3,767,978 |
| Steven W. Weldon – | Dec 21, 2020 | Sale(10b5-1 plan) | −50,000 | $0.30 | $15.00K | 3,853,700 |
| Steven W. Weldon – | Dec 21, 2020 | Sale(10b5-1 plan) | −50,000 | $0.33 | $16.50K | 3,803,700 |
| Steven W. Weldon – | Dec 18, 2020 | Sale(10b5-1 plan) | −50,000 | $0.30 | $15.00K | 3,903,700 |
| Steven W. Weldon – | Dec 17, 2020 | Sale(10b5-1 plan) | −50,000 | $0.31 | $15.50K | 3,953,700 |
| Steven W. Weldon – | Dec 17, 2020 | Sale(10b5-1 plan) | −50,000 | $0.30 | $15.00K | 4,003,700 |
| Steven W. Weldon – | Dec 16, 2020 | Sale(10b5-1 plan) | −50,000 | $0.30 | $15.00K | 4,053,700 |
| Steven W. Weldon – | Dec 15, 2020 | Sale(10b5-1 plan) | −50,000 | $0.30 | $15.00K | 4,153,700 |
| Steven W. Weldon – | Dec 15, 2020 | Sale(10b5-1 plan) | −50,000 | $0.30 | $15.00K | 4,203,700 |
| Steven W. Weldon – | Dec 15, 2020 | Sale(10b5-1 plan) | −50,000 | $0.32 | $16.00K | 4,103,700 |
| Steven W. Weldon – | Dec 14, 2020 | Sale(10b5-1 plan) | −50,000 | $0.28 | $14.00K | 4,350,000 |
| Steven W. Weldon – | Dec 14, 2020 | Sale(10b5-1 plan) | −46,300 | $0.29 | $13.43K | 4,253,700 |
| Steven W. Weldon – | Dec 14, 2020 | Sale(10b5-1 plan) | −50,000 | $0.29 | $14.50K | 4,300,000 |
| Steven W. Weldon – | Dec 11, 2020 | Sale(10b5-1 plan) | −50,000 | $0.25 | $12.50K | 4,450,000 |
| Steven W. Weldon – | Dec 11, 2020 | Sale(10b5-1 plan) | −50,000 | $0.26 | $13.00K | 4,400,000 |
| Bruce Wendel Director | Nov 16, 2020 | Buy | +3,268 | $3.14 | $10.26K | 3,268 |
| Tony Cataldo CEO, Director, 10% owner | Jun 2, 2020 | Sale | −4,234,320 | – | – | 6,500,000 |
| Steven W. Weldon CFO, Director | May 13, 2020 | Sale | −2,269,708 | – | – | 4,500,000 |
| Steven W. Weldon CFO, Director, 10% owner | Aug 14, 2019 | Award | +4,500,000 | – | – | 6,769,707 |
| Tony Cataldo CEO, Director, 10% owner | Aug 14, 2019 | Award | +7,000,000 | – | – | 10,734,320 |
| Tony Cataldo Director | Feb 6, 2019 | Sale | −800,000 | – | – | 4,029,600 |
| Raymond W. Urbanski CEO, Director | Feb 1, 2019 | Sale | −176,980 | – | – | 1,351,918 |
| Tony Cataldo Executive Chairman, Director, 10% owner | Nov 2, 2017 | Gift | −100,000 | – | – | 4,843,029 |
| Tony Cataldo Executive Chairman, Director, 10% owner | Nov 2, 2017 | Gift | −3,000,000 | – | – | 1,843,029 |
| Tony Cataldo Executive Chairman, Director, 10% owner | Nov 2, 2017 | Gift | −200,000 | – | – | 4,943,029 |
| Steven W. Weldon CFO, Director | Sep 1, 2017 | Award | +2,566,835 | – | – | 2,568,840 |
| Tony Cataldo Executive Chairman, Director, 10% owner | Sep 1, 2017 | Award | +5,129,660 | – | – | 5,143,029 |
| Investment Fund Ltd Bristol 10% owner | Apr 5, 2016 | Other | +250,000 | – | – | 463,806 |
| Investment Fund Ltd Bristol 10% owner | Apr 4, 2016 | Sale | −675,000 | $303750.00 | $205.03B | 1,525,472 |
| Theorem Group, LLC 10% owner | Dec 27, 2010 | Sale | −360,100 | $0.13 | $46.81K | 0 |
| Anshuman Dube Director, 10% owner | Dec 27, 2010 | Sale | −360,100 | $0.13 | $46.81K | 0 |
| Theorem Group, LLC 10% owner | Dec 23, 2010 | Sale | −339,900 | $0.13 | $44.19K | 360,100 |
| Theorem Group, LLC 10% owner | Dec 23, 2010 | Conversion | +700,000 | $0.05 | $35.00K | 700,000 |
| Anshuman Dube Director, 10% owner | Dec 23, 2010 | Conversion | +700,000 | $0.05 | $35.00K | 700,000 |
| Anshuman Dube Director, 10% owner | Dec 23, 2010 | Sale | −339,900 | $0.13 | $44.19K | 360,100 |
| Gary M. Post – | Aug 31, 2010 | Sale | −69,600 | $0.11 | $7.66K | 900,000 |
| Gary M. Post – | Aug 30, 2010 | Sale | −30,940 | $0.11 | $3.40K | 969,600 |
| Gary M. Post – | Aug 26, 2010 | Sale | −76,060 | $0.12 | $9.13K | 1,000,540 |
| Gary M. Post Secretary, Director | Jul 8, 2010 | Sale | −50,000 | $0.11 | $5.50K | 1,076,600 |
| Gary M. Post Secretary, Director | Jul 7, 2010 | Sale | −25,000 | $0.11 | $2.75K | 1,375,000 |
| Gary M. Post Secretary, Director | Jul 7, 2010 | Sale | −100,000 | $0.11 | $11.00K | 1,400,000 |
| Gary M. Post Secretary, Director | Jul 7, 2010 | Sale | −33,400 | $0.11 | $3.67K | 1,341,600 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of GT Biopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 42,579 shares on Sep 14, 2026 over the last 90 days.
See a number that looks wrong?